Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hesperidin in COVID-19 Symptoms
NCT04715932Phase 2Completed
- Sponsor
- Montréal Heart Institute
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hesperidin 1000mg with Placebo 1000mg (2 arms). Primary endpoint: Number of Subjects With COVID-19 Symptoms at 14 days. Started Feb 2021; status: completed.
02
Drugs
hesperidin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04715932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715932.